COVID Update: Masks are still required in health care settings, even if you’re fully vaccinated. Read our FAQs.
Local consolidative therapy (LCT) for selective oligometastatic cancers
Patrick W Linson, MD, MPH
The goal of this study is to learn if giving local consolidative therapy (LCT) up-front can better help to control oligometastatic disease, compared to a strategy of closely monitoring patients and waiting to give LCT at a later time point. LCT includes surgery, radiation, or other interventions.
Have had no more than 4 prior lines of systemic therapy administered to treat metastatic disease
Be 18 years of age on the day of signing informed consent
Have pathology confirmed diagnosis of cancer (Oligometastatic solid tumors)
Patients must not:
Have a diagnosis of active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe radiation therapy
Have known psychiatric or substance abuse disorders
Have metastatic effusion (e.g. pleural effusion or ascites)
Be pregnant or expecting to conceive within the projected duration of the trial at the screening visit
All treatments and physician visits will be conducted at the Scripps La Jolla site.
For more information, search for NCT03599765 at www.clinicaltrials.gov.